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Liver X receptors (LXRs) regulate lipogenesis and
inflammation, but their contribution to the metabolic
syndrome is unclear. We show that LXRs modulate
key aspects of the metabolic syndrome in mice.
LXRab-deficient-ob/ob (LOKO) mice remain obese
but show reduced hepatic steatosis and improved
insulin sensitivity compared to ob/obmice. Impaired
hepatic lipogenesis in LOKOmice is accompanied by
reciprocal increases in adipose lipid storage, reflect-
ing tissue-selective effects on the SREBP, PPARg,
and ChREBP lipogenic pathways. LXRs are essential
for obesity-driven SREBP-1c and ChREBP activity in
liver, but not fat. Furthermore, loss of LXRs in obesity
promotes adipose PPARg and ChREBP-b activity,
leading to improved insulin sensitivity. LOKO mice
also exhibit defects in b cell mass and proliferation
despite improved insulin sensitivity. Our data sug-
gest that sterol sensing by LXRs in obesity is critically
linked with lipid and glucose homeostasis and pro-
vide insight into the complex relationships between
LXR and insulin signaling.
INTRODUCTION
The metabolic syndrome is a constellation of interrelated disor-
ders including obesity, insulin resistance/diabetes, dyslipidemia,
fatty liver, hypertension, and atherosclerosis. The pathogenesis
of this syndrome is multifactorial, but lipid, glucose, and inflam-
matory dysfunction—manifested as obesity and insulin resis-
tance—appear to be central features (Olefsky and Glass,
2010). Excessive hepatic lipogenesis is a hallmark feature of
many models of obesity and diabetes, although the causal rela-
tionship between tissue lipid accumulation and insulin resistance
is unclear (Farese et al., 2012).
Liver X receptors (LXRs) are oxysterol-activated nuclear
receptors with important roles in lipid and glucose manage-106 Cell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc.ment. They direct cholesterol uptake, transport, and excretion
through the coordinate and tissue-selective regulation of their
target genes (Peet et al., 1998; Repa et al., 2000a; Tontonoz
and Mangelsdorf, 2003; Zelcer et al., 2009). LXRs are also cen-
tral regulators of SREBP-1c expression and de novo lipo-
genesis (Repa et al., 2000a, 2000b; Schultz et al., 2000). LXRs
integrate lipid and inflammatory signaling pathways in both
the innate and adaptive immune systems (Bensinger et al.,
2008; Hong et al., 2012; Joseph et al., 2003, 2004; A-Gonzalez
et al., 2009; Zelcer and Tontonoz, 2006). Ligand activation of
LXRs promotes cholesterol excretion (Peet et al., 1998; Schultz
et al., 2000; Tontonoz and Mangelsdorf, 2003) and reduces
inflammation, but simultaneously stimulates de novo lipogen-
esis of triglycerides (Repa et al., 2000a, 2000b; Schultz et al.,
2000), a potentially deleterious effect contributing to hepatic
steatosis and possibly hepatic insulin resistance (Grefhorst
and Parks, 2009).
Although LXRs are known to modulate many metabolic and
inflammatory pathways that could potentially influence the
development of diabetes and insulin resistance, the contribu-
tion of LXR signaling to the pathogenesis of the metabolic syn-
drome is still unclear. Ligand activation of LXRs in the setting of
diet-induced or genetic obesity improves whole-body glucose
disposal, both by improving peripheral glucose disposal into
fat via upregulation of glucose transporter type 4 (GLUT4)
and by indirectly suppressing hepatic gluconeogenesis (Com-
merford et al., 2007; Grefhorst et al., 2005; Laffitte et al.,
2003). But the in vivo contribution of LXR-dependent gene
expression in the setting of obesity and diabetes remains to
be established. A major obstacle to investigating these poten-
tial connections is the fact that LXR-null mice are resistant
to certain protocols of diet-induced obesity (Kalaany et al.,
2005) and lose adipose-tissue mass with age and cholesterol
accumulation (Bradley et al., 2007). Thus, it has been difficult
to examine the role of LXR signaling in a syndrome that has
obesity as a hallmark.
Previous work has shown that the LXR target gene, stearoyl
Co-A desaturase 1 (Scd1), is an important determinant of obesity
in leptin-deficient mice (Cohen et al., 2002). More recently, sup-
pression of the SREBP pathway in ob/ob (OB) mice by inactivat-
ing SCAP was reported to rescue hepatic steatosis, without
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Figure 1. Characterization of LOKO Mice
(A) WT, DKO, OB, and LOKOmice were weighed weekly. n = 10–11WT or DKO; n = 20–33 OB or LOKO. No significant weight differences between OB and LOKO
mice were observed.
(B) Size comparison of lean (WT) and obese (OB and LOKO) mice.
(C) At 24 weeks of age, mice were fasted for 12 hr, euthanized, and organs were harvested. Liver and WAT weights are shown normalized to total body weight
(n = 19 OB, 17 LOKO). Values are means ± SEM.
(D) Indirect calorimetry was performed on mice between 14 and 18 weeks of age. Mice were acclimatized to cages for 6+ hr, and data were then collected for an
additional 72 hr (n = 7 OB, 8 LOKO).
(E) Pooled plasma from OB and LOKO mice (n = 5–8) was analyzed by FPLC.
Statistical analysis was by two-way ANOVA with Bonferroni post hoc tests (A and E) or Student’s t test (C and D): **p < 0.01; ***p < 0.001; N.S., not significant.
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LXRs Regulate Lipogenesis in Obesityaffecting insulin resistance (Moon et al., 2012). Given that
LXRs are master transcriptional regulators of both SCD1 and
SREBP-1c, we expected that deletion of LXRs in the OB mouse
would affect multiple aspects of the metabolic syndrome and
might phenocopy SCD1 deficiency. Surprisingly, we show here
that mice deficient in both LXRa and LXRb, when bred onto
the OB background (ob/ob Lxrab/ [LOKO] mice), are not pro-
tected from obesity. However, they are completely protected
from hepatic steatosis and show dramatic improvement in insu-
lin sensitivity. LOKO mice trade reduced hepatic steatosis for
increased adipose-tissue mass and increased peroxisome pro-
liferator-activated receptor g (PPARg) signaling in fat. Paradoxi-
cally, LOKOmice are glucose intolerant and insulinopenic due to
impaired pancreatic responsiveness to a glucose challenge.
Collectively, our data provide insight into the complex relation-
ships between sterol sensing, LXRs, and insulin signaling path-
ways in obesity.RESULTS
LOKO Mice Are Obese but Protected from Hepatic
Steatosis
To determine the consequences of LXR deletion in obesity, we
analyzed wild-type (WT), Lxrab/ (DKO), OB, and LOKO mice.
Given the difficulty in generating these compound mutant ani-
mals—both OB mice and LXRb-null mice are sterile and must
be bred as heterozygotes—we chose to focus our analysis pri-
marily on male LOKO mice. All mice in this study were bred
onto a C57BL/6 background, backcrossed for ten or more gen-
erations. There were no differences in food consumption across
3 months of measurements (data not shown). Total body weight
was similar between OB and LOKO mice up to 24 weeks of age
(Figures 1A and 1B). However, internal organ sizes were mark-
edly different for both liver and fat (Figure 1C). LOKO livers
were not steatotic, and their normalized weights were reducedCell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc. 107
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Figure 2. LOKO Livers Are Rescued from Hepatic Steatosis
(A) Markers of hepatocellular necrosis (AST and ALT) were measured by colorimetric assay in WT, DKO, OB, and LOKO mice (n = 6–8 mice per group).
(B) LOKO livers are smaller and lack significant steatosis by gross examination.
(C) Representative H&E sections from OB and LOKO mice are shown. Magnification = 1003.
(D) Hepatic lipids were extracted and quantified from WT, DKO, OB, and LOKO mice (n = 5–6 mice per group).
(E) Hepatic gene expression was measured in WT, DKO, OB, and LOKO mice (n = 5–9 mice per group) at 24 weeks of age. Results are first normalized to
expression of the housekeeping gene 36B4 and shown as fold induction over WT animals.
Values are means ± SEM. Statistical analysis was by one-way ANOVA with Bonferroni post hoc tests: *p < 0.05; **p < 0.01; ***p < 0.001; N.S., not significant.
Cell Metabolism
LXRs Regulate Lipogenesis in Obesitycompared to OBmice. Conversely, the epididymal fat pads were
reciprocally increased in size, and total body adiposity was
increased in LOKO mice.
We determined nutrient utilization by housing mice in meta-
bolic chambers for 72 hr and calculating the respiratory quotient.
LOKO mice showed a trend toward carbohydrate oxidation, as
indicated by a higher respiratory exchange ratio (RER) of 0.935
versus 0.903 (Figure 1D; Figure S1A available online). There
was no difference in food consumption, but LOKO mice drank
significantly more water during these experiments (Figure S1B).
Correspondingly, LOKO mice showed increased movement in
the vertical axis, which would be required for increased access
to the water dispenser (Figure S1C). Fast protein liquid chroma-
tography (FPLC) was used for determining the serum cholesterol
and lipid profiles of the animals. LOKO mice have increased
plasma cholesterol and diminished circulating triglycerides108 Cell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc.compared to OB mice (Figures 1E and S1D). Plasma free fatty
acids were not different between the genotypes (Figure S1E).
This observation is consistent with established roles for LXRs
in governing cholesterol transport and excretion, as well as he-
patic lipogenesis (Bradley et al., 2007; Peet et al., 1998; Schultz
et al., 2000).
The gross liver weights were reduced in LOKOmice; therefore,
we analyzed lipid content and inflammation in more detail. At
24 weeks of age, aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), serum markers of hepatocellular dam-
age and necroinflammatory activity, tended to be elevated in
the plasma of LXR DKO compared to WT mice (Figure 2A),
consistent with the known hyperinflammatory state of these
animals (Beaven and Tontonoz, 2006). OB mice showed a
marked increase in both AST and ALT, but LOKO mice were
partially protected, suggesting reduced hepatic inflammation.
Cell Metabolism
LXRs Regulate Lipogenesis in ObesityAnalysis of inflammatory gene expression showed a trend
toward reduced expression of MCP-1 and CD68 (Figure S2A),
but the overall level of inflammatory transcript expression was
low in both groups, consistent with the mildly elevated AST
and ALT values. These results correlated with an almost com-
plete absence of steatosis in LOKO liver, both grossly (Figure 2B)
and histologically (Figure 2C). Although hepatic triglyceride con-
tent wasmarkedly reduced in LOKO livers, an increase in hepatic
cholesterol content was observed despite consumption of a reg-
ular chow diet (Figure 2D). Both of these findings are consistent
with the plasma cholesterol and triglyceride levels. Together,
these data establish that an intact LXR pathway is required for
the development of hepatic steatosis in OB mice.
To determine the molecular basis for the changes in hepatic
lipid accumulation, we analyzed gene expression by using real-
time PCR. LOKO livers showed a marked reduction in the
expression of genes related to hepatic lipogenesis, especially
Srebp1c, Scd1, Fas, Gk, and Elovl6 (Figure 2E). By contrast,
the expression of SREBP-2 and its downstream target genes
was largely preserved (Figure S2B). Genes involved in the
oxidation of fatty acids (Ucp2 and Ppara) were not significantly
altered, whereas enzymes related to thyroid hormone action
(Dio2, andDio3)were diminished (Figure 2E and data not shown).
We observed upregulation of Pepck and Foxo1, two genes with
well-recognized roles in hepatic gluconeogenesis, consistent
with LXR’s known function in suppressing gluconeogenesis
(Commerford et al., 2007; Laffitte et al., 2003). The expression
of insulin receptor substrate 2 (Irs2) was also increased in
LOKO livers, consistent with heightened insulin sensitivity. The
expression of insulin receptor, Irs1, and glucose-6-phosphatase
was unaffected by genetic loss of LXRs. Overall, the pattern of
gene expression in the liver revealed a marked reduction in the
lipogenic program.
Loss of LXRs Impairs b Cell Expansion in Response
to Obesity
Given recent data suggesting that hepatic lipid accumulation is
not always accompanied by insulin resistance (Minehira et al.,
2008; Monetti et al., 2007; Moon et al., 2012), we investigated
the consequence of LXR inactivation and amelioration of hepatic
steatosis on systemic glucose metabolism in obesity. There was
a trend toward fasting hyperglycemia and lower insulin in LOKO
mice after a 12 hr fast (Figure 3A). During random sampling of
nonfasting blood glucose concentrations, we observed marked
hyperglycemia in LOKOmice (Figure 3B). This was accompanied
by glycosuria assessed by urinalysis. In contrast, glucose was
undetectable in urine collected from OB and lean (WT or LXR
DKO) mice (Figure 3B and data not shown). Given that the gluco-
corticoid axis can affect circulating blood glucose and LXR defi-
ciency has been reported to impact corticosterone production
(Cummins et al., 2006), we measured corticosterone levels in
LOKO and OB mice and found no differences (Figure S3).
We next performed intraperitoneal (i.p.) glucose tolerance
tests (GTTs). LOKO mice showed impaired glucose tolerance,
and the blood glucose excursion over time was elevated even
compared to insulin-resistant OB mice (Figure 3C). Unexpect-
edly, this glucose intolerance correlated with a defect in sec-
ond-phase insulin secretion during the GTT. LOKO mice had
reduced fasting insulin at the start of the GTT and were unableto appropriately increase plasma insulin after exogenous
glucose administration. In fact, they exhibited an inappropriate
drop in insulin levels at 30 min into the GTT, a time at which
compensatory insulin production should be peaking. Glucose
intolerance in the face of insulinopenia strongly suggests that
loss of LXRs impairs pancreatic function in LOKO mice.
LOKO Mice Are Profoundly Sensitive to Exogenous
Insulin
To quantify peripheral insulin sensitivity and discriminate the
effects of LXR deletion on muscle and liver insulin action under
matched insulin exposure, we performed hyperinsulinemic-
euglycemic clamp studies. Animal weights and basal glucose-
turnover rates were not significantly different between OB
and LOKO mice (n = 15 and 8, respectively; Figure 3D). The
glucose-infusion rate required for maintaining euglycemia
(a measure of whole-body insulin sensitivity) was approximately
twice as high in LOKO compared to OB mice (27 ±
2.5 mg/kg/min versus 13 ± 1.4 mg/kg/min, p = 0.0001; Fig-
ure 3D). LOKO mice also showed a marked improvement in
insulin-stimulated suppression of hepatic glucose production
(HGP). In addition, the insulin-stimulated glucose disposal rate
(IS-GDR) into peripheral tissues (primarily muscle) was nearly
doubled in LOKO mice (15 ± 1.6 mg/kg/min versus 8 ±
1.6 mg/kg/min, p = 0.0113), indicative of markedly improved
peripheral insulin sensitivity. Improved insulin signaling was
confirmed in livers from LOKO mice, as phospho-Akt was sub-
stantially increased under the glucose-clamp conditions (Fig-
ure 3E). Collectively, these findings show that LXR deletion in
OB mice ameliorates hepatic and peripheral insulin resistance.
Furthermore, the endogenous pancreatic defect appears to be
the primary reason for glucose intolerance in LOKO mice, given
that they have improved peripheral glucose disposal when
insulin levels are not limiting.
To characterize the pancreatic defect in more detail, we iso-
lated pancreata from both lean and obese animals and per-
formed morphometric analysis of b cell mass and numbers.
Lean mice (WT or DKO) had relatively few insulin-positive endo-
crine islets scattered evenly throughout the pancreas (Fig-
ure S4A).We saw expansion of b cell mass in response to obesity
in both OB and LOKO mice (as expected), but the total b cell
mass and absolute number of b cells were substantially lower
in LOKO mice (Figures 3F and S4A). Interestingly, this finding
correlated with markedly reduced numbers of proliferating
b cells in LOKO mice, as revealed by Ki-67 immunostaining (Fig-
ure 3F). Apoptotic staining revealed very few TUNEL-positive
cells in either genotype and no overall differences (Figure S4B).
Due to the difficulty in generating LOKO animals, we were unable
to examine apoptosis in younger mice, and therefore cannot
exclude the possibility that increased b cell death may be a
contributor to the reduced numbers observed in LOKO islets.
Expression of LXR target genes in isolated islets (Srebp-1c,
Abca1, and Fas) was diminished, whereas insulin itself (Ins),
the b cell glucose transporter (Glut2), and a marker of b cell
development (Nkx2.2) were unchanged (Figure S4C). Previous
work in pancreatic cell lines has suggested that LXRb might
play a role in insulin secretion from b cells (Efanov et al., 2004;
Zitzer et al., 2006). We confirmed that in isolated pancreatic
islets, only LXRb is expressed and functional (Figures S5A andCell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc. 109
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Figure 3. LOKO Mice Are Glucose Intolerant but Insulin Sensitive
(A) Borderline fasting hyperglycemia and insulinopenia in LOKO mice. Mice were fasted overnight, glucose was measured by glucometer, and insulin was
measured by multiplexed bead assay (Luminex, Millipore) (n = 5 per group).
(B) Randomblood glucose levels from a separate group of OB and LOKOmice, showing significant hyperglycemia. Similar results were obtained in three separate
experiments. Glycosuria in LOKO mice is shown by chemical reaction with clinical urine test strips.
(C) GTTs were performed by i.p. injection of 1 mg/kg glucose into OB and LOKO mice (n = 5 per group) fasted for 6 hr. Time-course measurements of blood
glucose and insulin from the same experiment are shown. Values are means ± SEM. This experiment was repeated three times in two different cohorts of mice.
(D) LOKO mice are highly insulin sensitive in response to exogenous insulin. A separate cohort of OB (n = 15) and LOKO (n = 8) mice was analyzed by the
hyperinsulinemic-euglycemic clamp technique as described in the Experimental Procedures. Values are expressed as means ± SEM.
(E) Western blotting for hepatic Akt and its phosphorylated form (pSer473) showing increased basal pAkt expression in LOKO mice. Blotting was performed on
whole livers from individual animals (n = 3) of each genotype (OB and LOKO) under three conditions: (1) fasting for 6 hr (Fast), (2) fasting for 6 hr with a single i.p.
injection of insulin (12 U/kg) administered 30 min before sacrifice (Ins 30’), and (3) at the end of hyperinsulinemic-euglycemic clamps from Figure 3D (Clamp). A
single representative blot is shown. Band density was quantified by image analysis and expressed relative to the fasted OB animals.
(F) Quantification of total b cell mass from pancreatic sections stained for insulin production (n = 10–15 mice per genotype). Additional sections were
immunofluorescently stained for insulin and a proliferativemarker, Ki-67, and hand counted for cell numbers (n = 1011 for each genotype; n = 277,990 individual
b cells tabulated across all genotypes). The average number of b cells and proliferating (Ki-67+) b cells for each genotype are shown.
(G) Pancreatic islets were isolated from obesemice as described in the Experimental Procedures for glucose-stimulated insulin perifusion studies. After overnight
recovery, islets were exposed to a low basal level of glucose (4mM) for 40min and then switched into high-glucosemedia (16mM) for another 40min. Samples of
the perfusate were measured for islet-secreted insulin by ELISA (n = 3 separate channels per time point).
Statistical analysis was by Student’s t test (A, B, D, and F) or two-way ANOVA with Bonferroni post hoc tests (C and G): *p < 0.05; **p < 0.01; ***p < 0.001.
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LXRs Regulate Lipogenesis in ObesityS5B). To address the contribution of pancreatic LXR expression
to the LOKO phenotype, we performed real-time insulin-
secretion studies (‘‘perifusion’’ studies) on islets isolated from
OB mice with and without LXRb. Surprisingly, insulin secretion
in response to glucose was not affected by the loss of LXRb110 Cell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc.expression (Figure 3G), suggesting that LXR does not play an
essential role in insulin secretion per se, and that the relative
insulinopenia of LOKO compared to OBmice is probably a result
of decreased proliferation and/or survival of LXR-deficient b cells
in the setting of obesity.
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Figure 4. Activation of the Adipose PPARg Pathway in LOKO Mice
(A) H&E staining and gross morphology of epididymal fat pads from OB and LOKO mice. Magnification = 1003.
(B) Exon gene array profiling (Affymetrix) was performed on pooled RNA from WT, DKO, OB, and LOKO mice (n = 5–8 mice per group). Global gene expression
was filtered for genes showing at least a 2-fold change. Red demonstrates increased expression, whereas blue shows genes with decreased expression.
(C) Real-time quantitative gene-expression validation from WAT.
(D) Isotope-labeled glucose uptake in isolated fat pads from obese mice as described in the Experimental Procedures.
(E–G) ChREBP pathway gene expression (E), inflammatory gene expression (F), and insulin-stimulated gene expression (G) fromWAT in lean, obese, and obese
mice injected i.p. with a single dose of insulin (12 U/kg) 30 min before sacrifice (‘‘+ Ins’’).
Values aremeans ± SEM. Statistical analysis was by Student’s t test (C–F) or one-way ANOVA (G) with Bonferroni post hoc tests: *p < 0.05; **p < 0.01; ***p < 0.001.
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LXRs Regulate Lipogenesis in ObesityDe Novo Lipogenesis Is Shifted from Liver to Adipose
Tissue in LOKO Mice
Recent work showed that inactivation of the SREBP pathway in
liver does not improve insulin sensitivity despite reducing steato-
sis (Moon et al., 2012). In line with these results, supplementing
the diet of OB animals with the synthetic LXR ligand GW3965 for
either 2 or 4 weeks significantly improved the glucose-tolerance
profiles of OB mice, and these beneficial effects occurred
despite worsening hepatic lipogenesis (Figures S5C and S5D).
Thus, reduction of hepatic steatosis alone was unlikely to
account for the improved systemic insulin sensitivity in LOKO
mice. We therefore hypothesized that improved insulin sensi-
tivity in another tissue might be the primary basis for the meta-
bolic improvement. Because LOKOmice had increased adiposemass (Figure 1C), this prompted us to interrogate adipose-tissue
metabolism more closely.
LOKO mice exhibited visibly larger fat pads, consistent
with increased triglyceride storage in this tissue (Figures 1C
and 4A). The number and size of adipocytes was not obviously
different between the genotypes (Figure 4A and data not shown).
The increased fat-pad mass in LOKO mice was unexpected
given the reduction in hepatic lipogenesis and the fact that
SREBP-1c expression is responsive to LXR-agonist treatment
in adipose as well as liver. To clarify the basis for the adipose
phenotype, we performed transcriptional profiling on adipose
tissue. As expected, the expression of several adipose LXR
target genes, such as ApoD (Hummasti et al., 2004), was
reduced in LOKO mice (Figure 4B). Remarkably, and in contrastCell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc. 111
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for lipogenesis (Srebp1c, Scd1, Scd2, Acaca, Fasn, Dgat1, and
Dgat2) and lipid uptake (Pltp, Vldlr, Ldlr, Ldrap1, and Lpl,) were
increased in LOKO fat depots. These results were validated in
an expanded cohort of mice by real-time PCR (Figure 4C and
data not shown). This difference in adipose lipogenic gene
expression was not observed between WT and LXR DKO
mice, consistent with prior studies in lean animals (Kalaany
et al., 2005).
Surprisingly, LOKO mice also showed clear evidence of
enhanced PPARg activity, a pathway that is known to be a
powerful promoter of insulin sensitivity in OB mice. The expres-
sion of PPARg itself and of multiple PPARg target genes
(e.g., aP2, Adrp, Adiponectin, Olr1, Cd36, and Gpihbp1) was
increased in LOKO adipose tissue (Figures 4B and 4C). This
effect was tissue specific, in that expression levels of PPARg
were unchanged and expression of its target gene aP2 was
diminished in LOKO livers (data not shown). This was only
observed on the OB background and was not apparent when
comparing WT and LXR DKO mice on a B6 background (Fig-
ure 4B). Consistent with the known beneficial effects of the adi-
pose PPARg pathway on systemic glucose homeostasis, the
expression of genes related to insulin sensitivity and glucose
homeostasis (Insr, Irs1, Irs2, Irs3, Foxo1, Lipe, Glut4, and
Fatp1) was increased in LOKO fat (Figures 4B and 4C). Analysis
of glucose uptake in fat explants confirmed specific, increased
glucose uptake into adipose tissue of LOKO mice compared to
OB controls (Figure 4D). The expression of genes involved in
triglyceride mobilization (Hsl and Atgl) and of those encoding
lipid-droplet-associated-proteins (Adrp, Tip-47, S3-12, and
Lsdp5) was also higher in LOKO mice (Figure S6B). This obser-
vation is also consistent with activation of the PPARg pathway,
given that all of these are PPAR targets.
Recent work has highlighted an important role for the carbohy-
drate response element binding protein (ChREBP-b) in adipose
lipogenesis and insulin sensitivity (Herman et al., 2012). Surpris-
ingly, the expression of Chrebp-b was markedly increased in
adipose tissue from LOKO mice compared to OB controls (Fig-
ure 4E). The expression of Chrebp-a and its targets Rgs-16
and Txnipwas also elevated, albeit to a lesser degree (Figure 4E).
By contrast, Chrebp-b and Rgs-16 levels were decreased in
livers of LOKO mice (Figure S6A), consistent with prior work
showing that Chrebp is an LXR target gene in liver (Cha and
Repa, 2007). Together with the recent study by Herman et al.
(2012), these data strongly suggest that increased activity
of ChREBP-b contributes to the enhanced adipose-tissue lipo-
genic activity and insulin sensitivity of LOKO mice. Thus, loss
of LXR expression leads to increased activity of two major lipo-
genic transcription factor pathways, PPARg and ChREBP-b,
selectively in adipose tissue.
Given that inflammation has been postulated to play an impor-
tant role in adipose-tissue insulin resistance, we examined the
expression of macrophage markers in LOKO mice. Although
staining for F4/80-positive macrophages did not show obvious
differences between OB and LOKO mice by histology, more
sensitive analysis of macrophage-associated genes suggested
increased macrophage content and activity. There were
increased levels of mRNAs for macrophage surface proteins
(CD68) and cytokines characteristic of both classically (M1)112 Cell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc.and alternatively (M2) activated macrophages, including Ccl2,
Tnfa, Arg1, Il-6, iNos, and Cd274, in adipose tissue from LOKO
compared to OB mice (Figures 4B and 4F). Histologically, the
composition of the adipose tissue was similar between LOKO
and OB mice (Figure 4A). There were also increased levels of
circulating inflammatory mediators in LOKO mice (Figure S6C).
Thus, the improved adipose insulin sensitivity in LOKO mice
did not correlate with reduced macrophage infiltration or
reduced inflammatory profiles. This observation suggests that
increased macrophage content is not a dominant determinant
of adipose insulin sensitivity in all contexts and that increased
adipose lipid storage is beneficial, even in the setting of
increased inflammation.
We also examined the ability of insulin to regulate gene
expression in adipose tissue. Adipose Srebp-1c and Fasn
expression was refractory to insulin in OB mice (Figure 4G), pre-
sumably reflecting adipose-tissue insulin resistance (Diraison
et al., 2002; Grefhorst et al., 2005; Kim et al., 1998).Glut4 expres-
sion is also reduced in obese (OB) adipose tissue (Figure 4G)
(Grefhorst et al., 2005). Remarkably, the induction of Srebp-1c,
Fasn, Glut4, and Chrebp-b by insulin was enhanced in LOKO
mice, providing further evidence of improved adipose-tissue
insulin sensitivity (Figure 4G). Collectively, these data suggest
that PPARg and ChREBP-b pathway activation is a primary
cause of improved systemic insulin sensitivity in LOKO mice.
Our data also show that the LXR pathway is dispensable for
adipose SREBP-1c expression and lipogenesis in obesity and
that the absence of LXRs enhances the lipogenic response to
insulin in OB mice. These findings corroborate prior data
showing that the LXR pathway does not play a substantial role
in promoting PPARg expression or adipose-tissue mass (Hum-
masti et al., 2004), in that both of these parameters are increased
in the genetic absence of LXRs.
DISCUSSION
Although previous work has implicated LXRs in glucose homeo-
stasis, diabetes, and insulin secretion (Efanov et al., 2004; Gerin
et al., 2005; Laffitte et al., 2003; Mitro et al., 2007), no study has
directly addressed the role of LXRs in obesity-related diabetes.
In part, this is because LXR-null mice lose adipose-tissue mass
with age and are resistant to obesity. Kalaany et al. (2005)
showed that LXRa-null mice are resistant to obesity if choles-
terol is present in the diet and LXR DKO mice are refractory
to obesity when fed a high-fat diet (S.W.B., C. Hong, and
P.T., unpublished data). We have shown here that global LXR
deletion does not protect against genetic obesity but has dra-
matic effects on insulin sensitivity, pancreatic b cell mass, and
glucose homeostasis. Given that both Srebp1c and Scd1 are
direct LXR target genes, one might have expected LOKO
mice to phenocopy OB mice lacking these genes (Chu et al.,
2006; Cohen et al., 2002; Moon et al., 2012; Repa et al.,
2000a). However, in striking contrast to those models, loss of
LXRs in the setting of obesity shifts the program of de novo
lipogenesis from liver to fat, resulting in improved insulin sensi-
tivity. This phenotype mimics the effect of PPARg agonist
administration and can be traced to the induction of the adipose
PPARg pathway. Collectively, our data suggest that sterol
sensing by LXRs in obese states plays an important role in lipid
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syndrome.
We find that both hepatic lipid accumulation and insulin resis-
tance are strongly influenced by LXR expression in the setting of
obesity. Many studies have shown that hepatic lipid accumula-
tion correlates with both inflammation and insulin resistance
(Adams et al., 2005; Angulo and Lindor, 2001; Bard-Chapeau
et al., 2005; Chiang et al., 2009; Erion et al., 2009; Gutie´rrez-
Jua´rez et al., 2006; Jiang et al., 2005; Marchesini et al., 1999;
Savage et al., 2007; Schenk et al., 2008; Shoelson et al., 2007;
Yki-Ja¨rvinen, 2005). LOKO livers have reduced triglyceride accu-
mulation (steatosis) and inflammation and show improved insulin
sensitivity, consistent with the idea that hepatic lipid accumula-
tion may be a causal factor. But the relationship between steato-
sis and insulin sensitivity is controversial and context dependent;
several lines of evidence argue against a causal link. First, liver-
specific DGAT transgenic mice, in which the liver is overloaded
with triglycerides, do not show insulin resistance (Monetti
et al., 2007). Second, blocking VLDL secretion from the liver
does not alter insulin sensitivity or peripheral lipid storage (Mine-
hira et al., 2008). Third, it was recently demonstrated that OB
mice with liver-specific SCAP deficiency, in which all nuclear
forms of Srebp-1c, Srebp-1a, and Srebp-2 are eliminated, are
protected from hepatic steatosis but remain insulin resistant
(Moon et al., 2012). This latter result stands in stark contrast to
our findings and suggests that LXR signaling exerts effects on
glucose homeostasis independent of its activation of SREBP-1c
and its target genes in liver. It seems unlikely that triglycerides
and fatty-acyl lipids can be the sole determinants of hepatic
insulin sensitivity or that loss of hepatic SREBP-1c activity alone
can account for the metabolic phenotype of LOKO mice. Other
types of hepatic lipids may also impact insulin signaling (Scapa
et al., 2008), some of which may be under the control of LXRs.
Also, we have not excluded the possibility of an LXR-controlled
hepatic nonlipid signaling molecule (e.g., hormone or other
peptide) that mediates systemic insulin resistance. However,
our data are most consistent with the conclusion that reduced
hepatic triglyceride levels in liver cannot alone explain improved
insulin sensitivity in LOKO mice.
Our data point to improved adipose-tissue lipid storage and
PPARg pathway activation as the central mediators of improved
insulin sensitivity in LOKO mice. We have uncovered a connec-
tion between LXR signaling and the adipose PPARg and
ChREBP-b pathways in the setting of obesity. Activation of
PPARg in fat by thiazolidinedione ligands promotes adipose-
lipid storage and secondarily increases insulin sensitivity in liver
and muscle (Tontonoz and Spiegelman, 2008). Recently, a novel
isoform of ChREBP in adipose tissue has been shown to regulate
glucose metabolism and track with insulin sensitivity (Herman
et al., 2012). The ChREBP-b pathway is induced by GLUT4, itself
a target of both PPAR (Tontonoz and Spiegelman, 2008) and LXR
(Laffitte et al., 2003). Although hepatic de novo lipogenesis is lost
in LOKOs, there is a reciprocal increase of the same program
in adipose tissue, with a concomitant upregulation of PPARg,
ChREBP-b, and their downstream targets. With respect to insu-
lin sensitivity, the LOKO phenotype mimics the effect of PPARg
agonist administration and is consistent with the proposed bene-
ficial effects of adipose lipogenesis. Our data show that adipose
lipogenic gene expression, lipid storage, and adipogenesis arenot dependent on LXR expression as has been previously sug-
gested (Juvet et al., 2003; Seo et al., 2004). Moreover, we
show that loss of adipose LXR signaling actually leads to
compensatory upregulation of both the PPARg and ChREBP-b
in obese, but not lean, mice. We have therefore established
that LXRs act as physiologic suppressors of the PPARg and
ChREBP-b pathways, specifically in the obese state.
The ability of LXRs to regulate inflammation might also have
been expected to impact the metabolic phenotype of OB mice
(Zelcer and Tontonoz, 2006). Inflammatory signaling is postu-
lated to be an important determinant of insulin sensitivity, with
increased inflammation associated with insulin resistance (Arkan
et al., 2005; Cai et al., 2005; Saberi et al., 2009). LXRs are nega-
tive regulators of inflammation in several cell types, including
macrophages (Joseph et al., 2003; Tontonoz and Mangelsdorf,
2003) and nonparenchymal cells of the liver (Beaven et al.,
2011). We previously reported that loss of bone marrow LXRa
and LXRb expression did not alter insulin resistance in mice
fed a high-fat diet (Marathe et al., 2009). In the present study,
we show that loss of LXRs derepressed inflammatory marker
expression in obese adipose tissue and increased macrophage
content, but the tissue was still more insulin sensitive. It is impor-
tant to consider whole-body insulin sensitivity in LOKO mice in
light of both adipose-intrinsic and -extrinsic factors. In LOKO
fat, the increased PPARg signaling—a hallmark of improved
insulin sensitivity—exists despite a proinflammatory state in
this tissue. But multiple extrinsic improvements in liver (i.e., stea-
tosis, inflammation, and insulin sensitivity) are also potential
contributors to whole-body insulin sensitivity. The reciprocal
changes in hepatic and adipose inflammatory markers would
appear to negate each other in this model of obesity, suggesting
that changes in metabolism, rather than inflammation, play the
dominant role in determining insulin sensitivity, at least in this
context. We anticipate that liver- and adipose-specific knock-
outs for LXRs will be invaluable for further delineating the meta-
bolic dialog between hepatic steatosis and visceral adiposity.
A surprising and apparently paradoxical finding of this study is
that LOKOmice are glucose intolerant despite beingmore insulin
sensitive. The explanation for glucose intolerance in LOKO mice
is a pancreatic defect relating to total insulin quantity, as b cell
numbers and mass are reduced in LOKO mice (Figures 3F and
S4A). Improved insulin sensitivity in LOKO mice is offset by a
relative lack of insulin availability for their severe degree of
obesity (Figures 3A–3C). Despite having glycosuria, there is no
evidence that urinary glucose loss has a major impact on energy
homeostasis in LOKO mice, because they have identical body
weights (Figure 1A) and energy expenditures (Figure S1)
compared to OB mice. Other investigators have reported the
presence of increased urinary output in older (>12 months)
LXRb-deficient mice (Gabbi et al., 2012), and we also find that
LOKO mice have polydipsia, a hallmark finding of diabetes (Fig-
ures S1B and S1C). Previous papers have reported that loss of
LXR signaling compromises glucose-stimulated insulin secre-
tion (Chuang et al., 2008; Efanov et al., 2004; Gerin et al.,
2005; Zitzer et al., 2006). We therefore extended our studies to
examine freshly isolated LXR-deficient pancreatic islets exposed
to both low and high glucose and did not find a defect in their
ability to secrete insulin (Figure 3G). Instead, reduced b cell
mass (and therefore total b cell number) was linked to decreasedCell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc. 113
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in vivo evidence that LXRs have an important role in postnatal
b cell expansion in the setting of obesity.
Previously, it has been shown that LXR ligand activation
improves glucose disposal (Cao et al., 2003; Dalen et al., 2003;
Laffitte et al., 2003), but LXR agonists induce hypertriglyceride-
mia and hepatic steatosis by stimulating de novo lipogenesis in
the liver, and therefore first-generation LXR agonists are not an
attractive option for treating the metabolic syndrome (Beaven
and Tontonoz, 2006). The observation that global deletion of
LXRs improves muscle-, hepatic-, and adipose-tissue insulin
sensitivity in obesity raises the question ofwhether an LXRantag-
onist might have therapeutic utility for metabolic syndrome.
Given the beneficial effects of LXR activation on cholesterol
homeostasis and atherosclerosis, this seems unlikely. But the
question of how an LXR antagonist would affect metabolic ho-
meostasis in obese mice will nevertheless be important to inves-
tigate. In conclusion, our results demonstrate that LXR signaling
is pivotal in coordinating insulin sensitivity, fat storage, and b cell
mass in obesity. The integrated response to a glucose challenge
appears to involve complementary effects of the LXR isotypes in
different tissues. Future work with tissue-selective deletions of
LXRs should help further unravel these pathways.
EXPERIMENTAL PROCEDURES
Reagents
Synthetic LXR ligand GW3965 was provided by T. Willson (GlaxoSmithKline).
For animal-feeding experiments, GW3965 was compounded into standard
mouse chow (0.012%) and fed to mice for 10 days (Research Diets
D02061102CG).
Animals
Lxra/ and Lxrb/ mice on a C57/Bl6 background were originally provided
by D. Mangelsdorf (University of Texas Southwestern Medical Center, Dallas).
These animals were bred to ob/+ heterozygotes purchased from the Jackson
Laboratory and backcrossed for at least ten generations in our facilities at the
University of California, Los Angeles (UCLA). All animals were housed in a
temperature-controlled room under a 12 hr light/12 hr dark cycle under path-
ogen-free conditions. Mice had ad libitum access to water and standard chow
(Harlan Laboratories, NIH-31, 3.1 kcal/g, 23% calories from protein, 18% from
fat, and 59% from carbohydrate). Animals in this study were harvested at
24 weeks of age or between 16–18 weeks for islet cell isolations. All animal
experiments were approved by the Institutional Animal Care and Research
Advisory Committee of UCLA.
Indirect Calorimetry
Animals at 12, 16, or 20 weeks of age were housed individually in a series of
eight airtight chambers designed to assess the metabolic activity across three
light (12 hr)/dark (12 hr) cycles (Oxymax, Columbus Instruments). Animals were
acclimated to the chambers over the first 48 hr, and data were collected over
the subsequent 24 hr. The mice had free access to water and powdered food
presented from a food hopper attached to a scale, and the amounts of food
and water consumed were recorded. The rate of oxygen consumption (VO2)
and carbon dioxide production (VCO2) were calculated and averaged
over the entire final 24 hr period, as well as for the light and dark cycle, for
each mouse. The RER (an approximation of RQ) is calculated from the ratio
VCO2/VO2. Ambulatory activity was measured by interruption of dual-axis
infrared beams. Data were analyzed by Oxymax software provided by the
manufacturer (Columbus Instruments).
GTTs
For GTTs, mice were fasted for 6 hr prior to a single i.p. injection of glucose
(1 g/kg). Blood sugars were measured by a nick in a tail vein and analyzed114 Cell Metabolism 18, 106–117, July 2, 2013 ª2013 Elsevier Inc.on either a handheld glucometer (ACCU-CHEK, Roche Diagnostics) or
HemoCue blood glucose analyzer. For insulin determinations, a second
sample was taken at each time point, and serum was immediately separated
by centrifugation, with the aliquot snap frozen. Insulin levels were deter-
mined by an ultrasensitive mouse insulin ELISA kit according to the manu-
facturer’s instructions (Crystal Chem and Mercodia) or by multiplexed
bead assay (Luminex, Millipore). In some experiments, mice were fed a
diet containing GW3965 at 0.012% for 10 days. No difference in food
consumption was seen between animals fed the ligand-containing diet and
the reference diet.
Hyperinsulinemic-Euglycemic Clamps
Clamp studies to assess skeletal muscle and hepatic insulin sensitivity were
performed following a 6 hr fast on chronically cannulated (dual jugular
cannulae) mice as previously described (Hevener et al., 2003, 2007). The
glucose-turnover rate was calculated at basal and steady state during hyper-
insulinemia. In brief, at –90 min, a primed constant infusion of [3-3H] D-glucose
(PerkinElmer NET331; 5 mCi/hr) was initiated. At 0 min, a basal blood sample
was drawn from the tail for the determination of glucose-specific activity.
Following basal sampling, dextrose (50%) and insulin (25 mU 3 kg1 3
min1, Novolin, Novo Nordisk) plus tracer (5 mCi/hr) infusions were initiated
simultaneously, and glucose levels were clamped at euglycemia using a vari-
able glucose infusion rate. Rates of glucose appearance and disappearance
were calculated using the Steele equation for steady-state glucose kinetics
(Steele et al., 1959). Skeletal muscle and liver insulin sensitivity are reflected
by the IS-GDR and the insulin-stimulated percentage of suppression of
HGP, respectively. Differences in IS-DGR and HGP were detected by
ANOVA, with significance set a priori at p < 0.05.
Tissue, Serum, and Histologic Analysis
Animals were fasted for 6 hr prior to sacrifice, and blood was collected
by direct cardiac puncture with serum separated by centrifugation at
8,000 rpm for 5 min at 4C. ALTs and ASTs were determined by standard
colorimetric analysis at our core facilities (UCLA Department of Laboratory
and Animal Medicine). At the time of harvest, a small piece of liver was
snap frozen in liquid nitrogen for future RNA extraction. The largest lobe
of the liver was preserved for 24–48 hr in 10% formalin (w/v) and then trans-
ferred to 50% ethanol and kept at 4C until taken for sectioning and staining
with hematoxylin and eosin (H&E) by the UCLA Translational Pathology Core
Laboratory. The left epididymal white adipose tissue (WAT) pad was
weighed and frozen, as were the leg-muscle groups. The pancreas was
dissected out, trimmed of all connective tissue, and weighed. The entire
pancreas was fixed in 10% formalin (w/v) and then transferred to 50%
ethanol 24–48 hr later for sectioning and staining. Urine was analyzed for
glycosuria using rapid (30 s) reagent strips (Bayer). Plasma lipids were frac-
tionated using an FPLC system as previously described (Hedrick et al., 1993)
and quantified by area under the curve. Nonesterified fatty acid levels were
measured by a colorimetric enzymatic assay (Wako Pure Chemicals Indus-
tries) with standards prepared from 1 mM oleic acid. Optical density was
measured at 550 nm. Microscopic sections were viewed on a Zeiss Axio-
skop 2, and images were captured with a Zeiss charge-coupled device
camera using AxioVision software. For 2-deoxyglucose (2-DG) uptake into
isolated adipose tissue, pieces (0.3 cc) were sampled from perigonadal
fat and placed in Krebs-Henseleit buffer containing 0.1% BSA, 1 mM sodium
pyruvate, 1 mM mannitol, and 1 mM 2-DG. 3H-2-deoxy glucose (3 mCi/ml)
and 14C-mannitol (0.053 mCi/ml) were added to the incubation media for
30 min. Tissue was homogenized and glucose-uptake specificity was deter-
mined by comparison to mannitol uptake.
Pancreatic-Islet Morphology, Isolation, and Perifusion Studies
Pancreata removed at the time of sacrifice were embedded in paraffin and
longitudinally sectioned (4 mM) through the head, body, and tail through the
maximal width. Sections were stained for H&E and insulin (guinea pig anti-
insulin, 1:100; Zymed) as previously described (Janson et al., 1996). The
b cell mass was measured by first quantifying the pancreatic cross-sectional
area positive for insulin and then multiplying this by the pancreatic weight.
Primary islets were isolated from OB mice as previously described (Huang
et al., 2007). In brief, mice were euthanized with isoflurane, and the bile duct
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cannulated and perfused with a solution containing Hank’s balanced salt
solution (Invitrogen), 25 mM HEPES (Invitrogen), 0.23 mg/ml collagenase
(Liberase, Roche), and 0.1 mg/ml DNase (Roche). The pancreas was then
surgically removed and placed in a glass vial containing ice-cold collagenase
solution and digested for 20 min at 37C and dispersed by gentle agitation for
30 s. After washing, the islets were separated from the debris by differential
density centrifugation over Histopaque (Sigma-Aldrich). The islets migrated
at the medium-Histopaque interface, which was collected and washed, and
the islets were then handpicked under the microscope.
For specific insulin-secretion assays, mouse islets were isolated by the
method described above and recovered overnight in RPMI culture medium
supplemented in 11 mmol/l glucose and 10% fetal bovine serum at 37C in
humidified air containing 5% CO2. Islet perifusion experiments were per-
formed using a previously validated perifusion system (ACUSYST-S, Cellex
Biosciences) for measurements of insulin secretion. Isolated islets were first
exposed to 40 min of basal glucose perfusate (4mM glucose in Krebs-Ringer
bicarbonate buffer supplemented with 0.2% serum albumin, preheated to
37C, and oxygenated with 95%O2 and 5%CO2) followed by 40min of hyper-
glycemic perfusate (16 mM glucose). Each perifusion chamber contained
20 islets, and the effluent was collected in 4min intervals for subsequent deter-
mination of insulin concentrations by standard mouse insulin ELISA assay
(Mercodia) (Song et al., 2002).
RNA and Protein Analysis
RNA from tissue or isolated islets was extracted using TRIzol (Invitrogen)
according to the manufacturer’s directions. One microgram of total RNA
was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad).
SYBR Green (Diagenode) real-time quantitative PCR assays were performed
using an Applied Biosystems 7900HT sequence detector. Results are the
means of duplicate experiments (pancreatic islet cells) or the means of har-
vested groups of mice, normalized to 36B4. Specific primer sequences are
available upon request. For western blotting, liver homogenates were pre-
pared with RIPA lysis buffer containing protease inhibitors (cOmplete, Mini;
Roche), PMSF, NaF, and sodium orthovanadate. We separated 25 mg protein
by SDS-PAGE and transferred it to polyvinylidene fluoride membranes. These
were then probed with Akt, phosho-Akt, or tubulin antibodies (Cell Signaling
Technology). After horseradish-peroxidase-tagged secondary-antibody incu-
bation, chemiluminescence (ECL Plus, GE Healthcare) was used to detect
protein bands. Band density was quantified using ImageJ.
Statistical Analysis
Statistics were performed using Student’s t test (2 groups) or ANOVA
(>2 groups), with post hoc tests to compare to the control group. Data are
presented as means ± SEM and taken as statistically significant at p < 0.05.
SUPPLEMENTAL INFORMATION
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